Jennifer K. Litton

Oct 2, 2024 | digitalcommons.library.tmc.edu | Jennifer K. Litton |Meredith M. Regan |Lajos Pusztai |Hope Rugo

PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of adjuvant breast cancer (BC) end points. STEEP 2.0 identified a need to separately address end points for neoadjuvant clinical trials. The multidisciplinary NeoSTEEP working group of experts was convened to critically evaluate and align neoadjuvant BC trial end points.

Mar 8, 2024 | brnw.ch | Jennifer K. Litton

Jennifer K. Litton, MD, MHCM, medical oncologist, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges in determining the optimal sequencing of PARP inhibitors in patients with early-stage triple-negative breast cancer (TNBC) and provides examples of factors she considers when making this decision in clinical practice.

Mar 8, 2024 | onclive.com | Jennifer K. Litton

Jennifer K. Litton, MD, MHCM, medical oncologist, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges in determining the optimal sequencing of PARP inhibitors in patients with early-stage triple-negative breast cancer (TNBC) and provides examples of factors she considers when making this decision in clinical practice.

Nov 2, 2023 | brnw.ch | Kevin Kalinsky |Jennifer K. Litton

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kevin Kalinsky, MD: Hello. I'm Dr Kevin Kalinsky. Welcome to Medscape's InDiscussion series on triple-negative breast cancer (TNBC). Today we're discussing hereditary breast cancer, genetic testing, and therapeutic implications with Dr Jennifer Litton.

Nov 2, 2023 | medscape.com | Kevin Kalinsky |Jennifer K. Litton

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kevin Kalinsky, MD: Hello. I'm Dr Kevin Kalinsky. Welcome to Medscape's InDiscussion series on triple-negative breast cancer (TNBC).